BR112012011221A2 - biomarcadores para prever resposta rápida ao tratamento de hcv - Google Patents

biomarcadores para prever resposta rápida ao tratamento de hcv

Info

Publication number
BR112012011221A2
BR112012011221A2 BR112012011221A BR112012011221A BR112012011221A2 BR 112012011221 A2 BR112012011221 A2 BR 112012011221A2 BR 112012011221 A BR112012011221 A BR 112012011221A BR 112012011221 A BR112012011221 A BR 112012011221A BR 112012011221 A2 BR112012011221 A2 BR 112012011221A2
Authority
BR
Brazil
Prior art keywords
biomarkers
rapid response
hcv treatment
predict rapid
predict
Prior art date
Application number
BR112012011221A
Other languages
English (en)
Inventor
Shu-Hui Chiu
Yonghong Zhu
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112012011221A2 publication Critical patent/BR112012011221A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/186—Hepatitis C; Hepatitis NANB
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

biomarcadores para prever resposta rápida ao tratamento de hcv. a presente invenção refere-se a biomarcadores que são úteis para prever a resposta de pacientes infectados com vírus de hepatite c ao tratamento farmacológico.
BR112012011221A 2009-11-14 2010-11-11 biomarcadores para prever resposta rápida ao tratamento de hcv BR112012011221A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26132409P 2009-11-14 2009-11-14
PCT/EP2010/067252 WO2011058084A1 (en) 2009-11-14 2010-11-11 Biomarkers for predicting rapid response to hcv treatment

Publications (1)

Publication Number Publication Date
BR112012011221A2 true BR112012011221A2 (pt) 2016-04-05

Family

ID=43332770

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012011221A BR112012011221A2 (pt) 2009-11-14 2010-11-11 biomarcadores para prever resposta rápida ao tratamento de hcv

Country Status (14)

Country Link
US (1) US20110281747A1 (pt)
EP (1) EP2499493A1 (pt)
JP (1) JP2013511030A (pt)
KR (1) KR20120104239A (pt)
CN (1) CN102713630A (pt)
AU (1) AU2010317996A1 (pt)
BR (1) BR112012011221A2 (pt)
CA (1) CA2780044A1 (pt)
IL (1) IL219249A0 (pt)
MX (1) MX2012005528A (pt)
NZ (1) NZ599373A (pt)
RU (1) RU2012122637A (pt)
WO (1) WO2011058084A1 (pt)
ZA (1) ZA201203420B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130137084A1 (en) * 2011-11-28 2013-05-30 Roche Molecular Systems, Inc. Single Nucleotide Polymorphism on Chromosome 15 That Predicts HCV Treatment Responses
WO2013174988A1 (en) * 2012-05-24 2013-11-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting and monitoring treatment response in hcv- and hcv/hiv-infected subjects
JP6401702B2 (ja) 2012-09-07 2018-10-10 ザ・ガバナーズ・オブ・ザ・ユニバーシティー オブ・アルバータ 炎症性肝疾患の診断のための方法および組成物
RU2557534C2 (ru) * 2013-12-06 2015-07-20 Федеральное бюджетное учреждение науки научно-исследовательский институт Эпидемиологии Роспотребнадзора Способ прогнозирования ответа на противовирусную терапию при хроническом гепатите с

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
JPS6339752A (ja) 1986-08-02 1988-02-20 Kawada Tekko Kk インデツクス装置
US5981247A (en) 1995-09-27 1999-11-09 Emory University Recombinant hepatitis C virus RNA replicase
EA200700564A1 (ru) 1998-02-25 2007-08-31 Эмори Юниверсити 2`-фторнуклеозиды
ATE298317T1 (de) 1998-07-27 2005-07-15 Angeletti P Ist Richerche Bio Diketosäure-derivate als hemmstoffe von polymerasen
WO2000010573A1 (en) 1998-08-21 2000-03-02 Viropharma Incorporated Compounds, compositions and methods for treating or preventing viral infections and associated diseases
CN1324250A (zh) 1998-09-04 2001-11-28 维洛药品公司 治疗或预防病毒感染及其所致疾病的方法
JP2002525295A (ja) 1998-09-25 2002-08-13 バイロファーマ・インコーポレイテッド ウイルス感染および関連疾患の治療または予防法
AU1262001A (en) 1999-11-04 2001-05-14 Biochem Pharma Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
ATE357421T1 (de) 1999-12-24 2007-04-15 Asahi Glass Co Ltd Siliziumnitrid filter und verfahren zu dessen herstellung
AU2001235278A1 (en) 2000-02-18 2001-08-27 Shire Biochem Inc Method for the treatment or prevention of flavivirus infections using nucleoside analogues
US6727267B2 (en) 2000-04-05 2004-04-27 Tularik Inc. NS5B HVC polymerase inhibitors
ATE414520T1 (de) 2000-04-13 2008-12-15 Pharmasset Inc 3 oder 2 hydroxymethyl substituierte nucleoside derivate und ihre verwendung zur behandlung von virusinfektionen
JP2004509066A (ja) 2000-05-10 2004-03-25 スミスクライン・ビーチャム・コーポレイション 新規抗感染症薬
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
CA2410579C (en) 2000-05-26 2010-04-20 Jean-Pierre Sommadossi Methods and compositions for treating flaviviruses and pestiviruses
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
KR101005299B1 (ko) 2000-10-18 2011-01-04 파마셋 인코포레이티드 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드
JP2005502580A (ja) 2000-12-15 2005-01-27 フアーマセツト・リミテツド フラビウィルス感染治療用抗ウィルス薬
HUP0400726A3 (en) 2001-01-22 2007-05-29 Merck & Co Inc Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
KR100798579B1 (ko) 2001-03-31 2008-01-28 동화약품공업주식회사 신규의 메톡시-1,3,5-트리아진 유도체 및 그를 포함하는약학적 조성물
AR036081A1 (es) 2001-06-07 2004-08-11 Smithkline Beecham Corp Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
EP2206709A3 (en) 2001-06-11 2011-06-29 Virochem Pharma Inc. Thiophene derivatives as antiviral agents for flavivirus infection
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
JP4558314B2 (ja) 2001-07-20 2010-10-06 ベーリンガー インゲルハイム （カナダ） リミテッド ウイルスポリメラーゼインヒビター
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US6899700B2 (en) 2001-08-29 2005-05-31 Kimberly-Clark Worldwide, Inc. Therapeutic agent delivery tampon
WO2003026589A2 (en) 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
EP1438054A4 (en) 2001-09-28 2006-07-26 Idenix Cayman Ltd METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUS AND PESTIVIRUS USING MODIFIED NUCLEOSIDE AT 4 'POSITION
WO2003037262A2 (en) 2001-10-29 2003-05-08 Smithkline Beecham Corporation Novel anit-infectives
AU2003248566A1 (en) 2002-05-24 2003-12-12 Smithkline Beecham Corporation Novel anti-infectives
AU2003251524A1 (en) 2002-06-17 2003-12-31 Isis Pharmaceuticals, Inc. Carbocyclic nucleoside analogs as RNA-antivirals
ES2469569T3 (es) 2002-06-28 2014-06-18 Idenix Pharmaceuticals, Inc. Prof�rmacos de nucle�sidos modificados en 2' y 3' para el tratamiento de infecciones de Flaviviridae
MXPA04012779A (es) 2002-06-28 2005-08-19 Idenix Cayman Ltd Profarmacos de 2'- y 3'-nucleosido para tratar infecciones por flaviviridae.
RS113904A (en) 2002-06-28 2007-02-05 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
EP1556399A4 (en) 2002-07-16 2007-09-26 Merck & Co Inc NUCLEOSIDE DERIVATIVES AS RNA-DEPENDENT VIRAL RNA POLYMERASE INHIBITORS
AU2003256619A1 (en) 2002-07-24 2004-02-09 Isis Pharmaceuticals, Inc. Pyrrolopyrimidine thionucleoside analogs as antivirals
EP1560827B1 (en) 2002-11-01 2010-12-29 Abbott Laboratories Anti-infective agents
CN1849142A (zh) 2002-11-15 2006-10-18 埃迪尼克斯(开曼)有限公司 2′－支链核苷和黄病毒突变
AU2003300957A1 (en) 2002-12-11 2004-06-30 Smithkline Beecham Corporation Anti-infectives
AU2003300956A1 (en) 2002-12-11 2004-06-30 Smithkline Beecham Corporation Anti-infectives
AU2004226052B2 (en) 2003-03-31 2009-06-11 Toto Ltd. Surface-modified titanium dioxide fine particles and dispersion comprising the same, and method for producing the same
WO2005009418A2 (en) 2003-07-25 2005-02-03 Idenix (Cayman) Limited Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
JP2008151505A (ja) * 2005-04-05 2008-07-03 Biomarker Science:Kk インターフェロン療法の有効性判定方法及び判定用キット
AU2009240021B2 (en) * 2008-04-21 2013-01-10 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Antiviral therapy
CN102257159A (zh) * 2008-12-18 2011-11-23 弗·哈夫曼-拉罗切有限公司 用于hcv治疗应答的生物标志物

Also Published As

Publication number Publication date
KR20120104239A (ko) 2012-09-20
US20110281747A1 (en) 2011-11-17
NZ599373A (en) 2013-04-26
JP2013511030A (ja) 2013-03-28
EP2499493A1 (en) 2012-09-19
CN102713630A (zh) 2012-10-03
IL219249A0 (en) 2012-06-28
ZA201203420B (en) 2013-03-27
RU2012122637A (ru) 2013-12-20
AU2010317996A1 (en) 2012-05-10
MX2012005528A (es) 2012-06-12
WO2011058084A1 (en) 2011-05-19
CA2780044A1 (en) 2011-05-19

Similar Documents

Publication Publication Date Title
CY2015012I1 (el) Αναστολεις του ιου της ηπατιτιδας c
DK3470077T3 (da) Fremgangsmåde til forudsigelse af respons på behandling af sygdomme med farmakologiske chaperoner
DK2509684T3 (da) Anordning til behandling af rhinitis ved biostimulerende belysning
DK2252148T3 (da) Fremgangsmåder til behandling af irritabel tarmsyndrom
UY34851A (es) Inhibidores macrocíclicos de virus flaviviridae
DK2245027T3 (da) Hepatitis C-virusinhibitorer
BRPI1006847A2 (pt) desenvolvimento de um construtor de hidroxicarboxilato de alumínio.
DK2452740T3 (da) Fremgangsmåde til behandling af udstødningsgas ved anvendelse af gasformig jod
BRPI1008851A2 (pt) processamento de gás hidrocarboneto
BR112012005438A2 (pt) inibidores de vírus flaviviridae
BR112012001931A2 (pt) métodos para diagnosticar ou prever o resultado de hepatite c em pacientes infectados com hcv
SI2427576T1 (sl) Generični testi za odkrivanje virusov influence
DK2780102T4 (da) Understøttet ædelmetalkatalysator til behandling af udstødningsgas
BR112012011221A2 (pt) biomarcadores para prever resposta rápida ao tratamento de hcv
ES2549483T8 (es) Escudo térmico metálico estructurado
BRPI1007966A2 (pt) vedação de cadinho de plasma.
BR112012011393A2 (pt) biomarcadores para a previsão da resposta sustentada ao tratamento de hcv
MX2016007884A (es) Biomarcadores para la respuesta al tratamiento del hbv.
IT1401158B1 (it) Piano cottura
ES1073743Y (es) Teclado táctil multilenguaje
CN301184808S (zh) 嵌入式燃气灶具(q636a)
TH105924B (th) สารยับยั้งไวรัสตับอักเสบ c
DOP2009000008A (es) Cocina o estufa de alcohol no presurizado
BR112012001375A2 (pt) inibidores de vírus flaviviridae
TR200808016T1 (tr) Bir fırın

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]